JUN and neoplasm: We observed a significant negative correlation between the relative increase in the tumor diameter and the tumoral c-Jun expression level in PDAC patients receiving the irbesartan plus GEM/nab-paclitaxel regimen in Cohort3# and Cohort4# (Fig. 11M).